Document is current
Any future updates will be listed below
-
Authors
Annunziata, Maria Carmela
Barbareschi, Mauro
Bettoli, Vincenzo
Dall’Oglio, Federica
Micali, Giuseppe
Monfrecola, Giuseppe
Skroza, Nevena https://orcid.org/0000-0003-4478-5404
Tretti Clementoni, Matteo
Veraldi, Stefano
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 12 December 2024
First Online: 9 January 2025
Declarations
:
: Dr. Barbareschi, Dr. Micali and Dr. Monfrecola have no competing interests to declare. Dr. Annunziata has acted as a consultant for Bionike, Pierre Fabre and La Roche Posay. Dr. Bettoli has acted as a consultant, advisory board member and/or investigator for Exeltis, Menarini, AbbVie, Beiersdorf, Biogena, Difa Cooper, Galderma, Ganassini, Giuliani, L'Oréal, Pierre-Fabre, Novartis and UCB. Dr. Dall’Oglio has acted as a consultant for Eli Lilly, AbbVie, Cantabria Labs, Difa Cooper, La Roche Posay, Pierre Fabre and Bioderma. Dr. Skroza has acted as a consultant, advisory board member and/or investigator for AbbVie, Boehringer-Ingelheim, Galderma, Janssen, Leo Pharma, L'Oréal, Novartis and Sanofi. Dr. Tretti Clementoni has acted as a consultant for Lumenis, Quanta System, ExoCobio, Deka, Galderma, Sinclair, Sofwave, and Lutronic. Dr. Veraldi has acted as a consultant for Bionike, BMG Pharma, Cantabria Labs Difa Cooper, Cieffederma, Damor, Exeltis, Ganassini, GD, Ideka, La Roche Posay, Substipharm, and Tillomed. None of the authors has competing interests to declare regarding this study.
: Ethics committee approval was not required because this article is based on previously conducted studies. Patients and/or guardians provided written informed consent for the publication of the images.
